Phaseline

Companies › Zhuhai Rui-Inno Pharmaceutical Technology

Zhuhai Rui-Inno Pharmaceutical Technology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MDI-1228-mesylate gel–Phase 2Diabetic Foot Ulcer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06852976MDI-1228-mesylate gelPhase 2Diabetic Foot UlcerMetabolic and endocrineDec 2025

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Tonghua Dongbao Pharmaceutical Portal Therapeutics Op-T Housey Healthcare ULC Mankind Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.